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Abstract
Indonesia faces high burden of Tuberculosis (TB) each year. At the same time, smoking is 
considered to be common, especially in men. A number of TB patients, who receive standard 
regimen of TB therapy, would not easily give up on smoking, despite extensive advices from 
healthcare providers. This report aims to show evidence whether cigarette smoking increases the 
rate of treatment failure of standard anti-TB regiment in patients with pulmonary TB. Systematic 
search was done in two databases: Medline® and Scopus. Cohort studies were selected as 
appropriate study design to answer a prognosis question. Two cohort studies are found to be 
relevant with this report. Treatment failures upon standard regimen of TB therapy are 6.9% and 
1.7% in both studies. Smoking habit has been demonstrated to increase the likelihood of treatment 
failure with OR 2.37 (95% CI: 1.24 – 4.54) and 7.489 (95% CI: 0.93 – 60.30). In conclusion, 
treatment failure in standard TB therapy is small. Smoking habit increases the treatment failure of 
standard anti-TB regiment in patients with pulmonary TB.
Keywords: smoking, tuberculosis, treatment failure
Peran Kebiasaan Merokok dalam Kegagalan Pengobatan Tuberkulosis
Abstrak
Setiap tahun Indonesia menghadapi beban tinggi tuberkulosis (TB) paru. Pada saat yang 
sama merokok dianggap sebagai kebiasaan umum, terutama pada populasi laki-laki dewasa. 
Penderita TB yang merokok cenderung tidak menghentikan kebiasaan buruknya walaupun sudah 
mendapat edukasi dari petugas kesehatan. Laporan kasus berbasis bukti ini bertujuan untuk 
menyajikan bukti bahwa merokok meningkatan kegagalan pengobatan TB pada penderita dalam 
regimen standar anti-TB. Pencarian sistematis dilakukan melalui database elektronik Medline® dan 
Scopus. Penelitian kohort dipilih sebagai jenis penelitian yang sesuai untuk menjawab pertanyaan 
prognosis pada studi ini. Terpilih dua penelitian berbasis kohort yang ditelaah dalam laporan ini. 
Dalam penelitian tersebut tingkat kegagalan pengobatan TB dengan regimen standar adalah 6,9% 
dan 1,7%. Kebiasaan merokok meningkatkan kegagalan pengobatan TB dengan OR 2,37 (95% 
CI: 1,24 – 4,54) dan 7,48 (95% CI: 0,93 – 60,3). Disimpulkan proporsi kegagalan pada terapi 
standar anti-TB tidak besar. Kebiasaan merokok meningkatan tingkat kegagalan pengobatan pada 
penderita TB.
Kata kunci: merokok, tuberkulosis, gagal pengobatan
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Introduction
Tuberculosis (TB) remains a major leading 
cause of death in Indonesia, accounting of almost 
a tenth of all deaths.1 Approximately 539.000 new 
cases of TB are accounted in yearly which make 
Indonesia ranks number five in the world.2 This 
alarming number is coupled with the increasingly 
prevalent tobacco smoking in Indonesia.3 In 
Indonesia, 65.9% of adult men smoke which 
contribute to total smokers of 34% of the 
population. Smoking is known to adversely affect 
clinical manifestations and disease progression of 
TB.4 Another main concern is that smoking may be 
associated with poor adherence to TB treatment. 
TB treatment failure subjects the patient for 
further time consuming and expensive treatment, 
with the concomitant risk for developing multi 
drugs-resistant TB (MDR-TB). TB management 
guideline used in Indonesia does not strongly 
emphasize on the importance of smoking cessation 
for TB patients. 
The objective of this paper is to evaluate the 
effect of patients’ smoking habit to TB treatment 
failure by means of appraising available medical 
evidences. The clinical question is “Does cigarette 
smoking increase the treatment failure of standard 
anti-TB regiment in patients with pulmonary 
tuberculosis (TB)?”
Clinical Case
An Indonesian 35 years old male came 
to Duren Sawit Primary Health Care Center 
(Puskesmas) with a chief complaint of chronic 
cough, accompanied with a slight reduction of body 
weight (from 55 kg to 53 kg in 1 month). History 
of night sweat and bloody cough was denied. 
The patient smokes two packs daily since he was 
17 years old. His wife has been diagnosed with 
pulmonary tuberculosis (TB) one month prior. The 
patient’s sputum examination revealed positive 
finding for acid fast bacilli. Consequently, standard 
anti-TB regimen therapy was immediately initiated. 
Despite the physician’s advice to stop smoking, the 
patient continues to resume his deleterious habit.
Discussion
Two databases, Medline® and Scopus, 
were searched to identify studies evaluating the 
influence of cigarette smoking to TB treatment 
outcome. Eighty-three citations were identified 
from the searches, 72 from Medline® and 11 from 
Scopus. Two articles were finally included in this 
report based on the inclusion and exclusion criteria. 
Critical appraisal was performed utilizing the Oxford 
model of evidence based medicine.
Tachfouti et al,5 performed a prospective cohort 
study to evaluate the impact of smoking on the failure 
rate of patients with TB. The trial was conducted 
in 15 TB control units (TCUs) in public primary 
and respiratory care centers in urban settings in 
Morocco. The diagnosis of TB was confirmed if the 
patients presented with symptoms of fever or cough 
and a sputum smear that showed acid-fast bacilli or 
a chest radiograph that showed changes compatible 
with a diagnosis of TB. A questionnaire was used 
to assess: (1) socio-demographic characteristics, 
(2) smoking status, and (3) alcohol consumption. 
All subjects in this study received combination anti-
tuberculosis drug treatment and ancillary clinical 
care and follow-up for TB according to international 
guideline.5 The study observed an overall proportion 
of treatment failure of 6.9%; it is significantly higher 
among smokers (9.1% vs. 4.5%; OR 2.37, 95% 
CI 1.24–4.54, p0<.01).  There was no significant 
difference, however, between heavy and light 
smokers, or between non-smokers and passive 
smokers. After adjustment for socioeconomic 
variables (age and monthly income), clinical form 
of TB and alcohol consumption to exclude the 
possibility of confounding, smoking status remained 
significantly associated with treatment failure with 
aOR of 2.25 (95% CI 1.06-4.76; p<0.03).
       Table 1. Assessment of Validity
Validity MoroccanTachoufti et al6
Malaysian
Dujaili et al7
Was a defined, representative sample of patients 
assembled at a common (usually early) point in the course 
of their disease?
 
Was patient follow up sufficiently long and complete?
ü
(30% loss to follow up)

Were objective outcome criteria applied in a “blind” 
fashion?  Not mentioned
If subgroups with different prognoses are identified, was 
there adjustment for important prognostic factors?  
Was there validation in independent group (“test-set”) of 
patients?  
Are the results of this prognosis study valid?  
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Dujaili et al6 performed a retrospective cohort 
study in Malaysia to determine the prevalence 
of smoking among TB patients in Penang and to 
compare the treatment outcomes between smoking 
and non-smoking TB patients. The subjects were 
grouped into either ever smokers (those who 
currently smoke cigarettes at the time of diagnosis 
of TB or who had previously quit smoking) or 
never smokers (those who never smoked or who 
have smoked less than 100 cigarettes during their 
lifetime). Unlike the trial in Morocco, the outcome 
measures evaluated in this study were: cured, 
treatment completion, treatment default, treatment 
failure and death. A TB patient is defined as cured if 
he/she is smear-negative at/or 1 month prior to the 
completion of treatment and on at least one previous 
occasion. In addition, a patient who has completed 
treatment but without proof of cure is considered 
as a case of treatment completion. A patient 
whose treatment was interrupted for 2 months or 
more is referred to as a case of treatment default, 
whereas death was defined as a patient who dies 
for any reason during the course of treatment. The 
patients’ socio-demographic data, co-morbidities 
and clinical characteristics were collected by 
a retrospective review and assessment of the 
patients’ medical records were carried out in order 
to evaluate treatment outcomes. In this study, ever-
smoking TB patients were about seven times more 
likely to fail or default treatment (OR 7.489, 95% 
CI 0.93–60.30, p=0.039 and OR 7.176, 95% CI 
2.76–18.62, p<0.001 respectively). They were also 
      Tabel 2. Assessment of Importance





How likely are the outcomes over time?
Overall failure 6.9% 1.7%
In smoking 9.1% 2.9%
In no smoking 4.5% 0.4%
Risk difference
(smoking – no 
smoking)
4.6% 2.5%
crude OR 2.37 7.489
How precise are the estimate? 95% CI (1.24 – 4.54) (0.93 – 60.30)






Were the study patients similar to your own?  
Will this evidence make a clinically important impact on 
your conclusions about what to offer or tell your patient?  
less likely to be cured from TB compared to never 
smokers (OR 0.342, 95% CI 0.21–0.49, p<0.001). 
After adjustment for the effects of confounders 
(age, sex, alcohol consumption, IVDU and history of 
chronic diseases including cyanotic heart disease, 
liver disease, chronic renal failure, malabsorption 
syndrome, cancer, steroids treatment and others), 
ever smokers were still significantly less likely to be 
cured (aOR 0.312, 95% CI 0.17–0.57, p<0.001) and 
more likely to default treatment (aOR 3.249, 95% 
CI 1.01–10.45, p<0.048). The risk of a smoker to 
die from TB or to fail treatment was statistically not 
significant (aOR 0.962, 95% CI 0.48-1.92, p=0.912 
and aOR 13.593, 95% CI 0.59-308.69, p=0.101).
The evidence concerning the association of 
smoking status with undesirable TB treatment 
outcome (i.e. treatment failure) is consistent: 
Tachfouti et al5 presented OR and aOR of 2.37 
(95% CI 1.24–4.54, p<0.01) and 2.25 (95% CI 1.06-
4.76; p<0.03), respectively; Dujaili et al6  shown an 
OR of 7.489 (95% CI 0.93–60.3, p=0.039) and aOR 
of 13.593 (95% CI 0.59-308.69, p=0.101).
A number of important drawbacks are inherent 
in the critically appraised study. Tachfouti et al5 
encountered a high percentage of missing data, 
19.2% drop out and 10.9% loss to follow-up (Table 
2). This instance can distort the study results and 
subsequently its final conclusion. Dujaili et al6 on 
the other hand, presented a very wide CI for the 
univariate assessment and multivariate binary 
logistic regression analysis of the association of 
tobacco smoking to treatment failure in TB patients. 
Susanto AP, Sani AA, Supit T, Utama NH, Andika R, Arista TH, Moegni F eJKI
48
A wide 95% CI indicates poor precision of the OR. It 
is also important to note that the 95% CI overlapped 
the null value both in univariate and multivariate 
analyses, thus they failed to reach statistical 
significance. Still, it does not prove absence of 
association between smoking status and rate of 
treatment failure.
Our patient is a smoker diagnosed with TB, 
now receiving anti-TB drug category I and refused 
to quit smoking. Based on two studies found, he will 
have poorer prognosis compared to non-smokers 
and more likely to fail or default treatment and less 
likely to be cured. Whether the likelihood of future 
outcomes will be altered if he quit smoking now is 
still a question. Nevertheless, smoking cessation 
have been proved to lower risk of cardiovascular, 
cerebrovascular, chronic obstructive pulmonary 
disease, and other pulmonary infections than TB.8
Conclusion
Smoking is associated with undesirable TB 
treatment outcome; treatment failure. Results from 
discussed trials suggested that smoking cessation 
may be beneficial to improve the success rate of 
TB treatment regiment and improve the patients’ 
overall health.
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